| 摘要 |
Provided herein are compounds represented by the Formula (I) that are useful for the treatment of migraine. The compound having the formula (I): has RI at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, thiomethoxy, -NHA, -NA2,-NHC(=O)A, aminocarbonyl, -C(=O)NHA, -C(=O)NA2, halogen, hydroxy, -OA, cyano or aryl; A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl; R2 is represented by (i), (ii), (iii), or (iv) wherein, R3 is independently at each position represented by-H, optionally substituted Cl-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-6cycloalkyl or AOH; n is 2, 3 or 4; P is a heterocyclic ring; R6 is -H or methyl; Y is -C(=O)NH-, -C(=O)NA-, -C(=O)N(A)-, -NHC(=O)-, -C(=S)NH-, -CH2NH-, -C(=O)-, -C(=O)CH2-, -CH2C(=O)-, -C=(O)- piperazine-, -NAC(=O)-, -C(=S)N(A)-, CH2NA, NACH2 or a 5-membered heterocyclic. R7 is a monocyclic or bicyclic aromatic ring or a heterocycle optionally substituted by one or more substituents selected from R8, R9 and Rl0; wherein R7 is connected to Y either by a single bond or by a ring fusion; R8 is-CH2-, -C(=O)-, -SO2-, -SO2NH-, -C(=O)NH-, -O-, -S-, -S (=O)-, a single bond as tether from R7 to R9, or a five membered heterocyclic connected to R7 by either a single bond or by ring fusion; R9 is optionally substituted heterocycle, optionally substituted aryl, optionally substituted piperazinyl-R11, optionally substituted morpholinyl-R11 or optionally substituted thiomorpholinyl or-C(=O)A; R10 is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen,-C(=O)NH2-, methylthio, -NHA, -NA2, -NHC(=O)A, C(=O)NHA, C(=O)NA2, or OA; R11 is -H, alkyl, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C(=O)R9, -alkylR9, C(=O)A, C(=O)NH2, C(=O)NHA, C (=O) NA2 or -C(=O)OA; or a pharmaceutically acceptable salt of the compound. Also provided are processes for the preparation of compounds of Formula (I) and its intermediates.
|
